2-(4-氨基-苯氧基)-1-哌啶-1-基-乙酮 | 76870-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(4-氨基-苯氧基)-1-哌啶-1-基-乙酮
• 英文名称: 2-(4-aminephenoxy)-1-(piperidin-1-yl)ethanone
• 英文别名: 2-(4-Amino-phenoxy)-1-piperidin-1-yl-ethanone；2-(4-aminophenoxy)-1-piperidin-1-ylethanone
• CAS: 76870-14-9
• 化学式: C₁₃H₁₈N₂O₂
• mdl: MFCD06662317
• 分子量: 234.298
• InChiKey: LBCGJRYQWQTFIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  维A酸 、 2-(4-氨基-苯氧基)-1-哌啶-1-基-乙酮 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 (2E,4E,6E,8E)-3,7-dimethyl-N-[4-(2-oxo-2-piperidin-1-ylethoxy)phenyl]-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenamide
  参考文献：
  名称：

  Fenretinide Derivatives Act as Disrupters of Interactions of Serum Retinol Binding Protein (sRBP) with Transthyretin and the sRBP Receptor

  摘要：

  Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions. A series of retinoid analogues were synthesized and examined for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. A number inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development. Shortening the chain length of the FEN derivative substantially abolished binding to sRBP, indicating that the strength of the interaction the polyene chain region. Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compounds on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.

  DOI：

  10.1021/jm200256g
• 作为产物：
  描述：

  4-硝基苯氧乙酸 在 氯化亚砜 、 palladium 10% on activated carbon 、 氢气 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、400.01 kPa 条件下， 反应 2.0h， 生成 2-(4-氨基-苯氧基)-1-哌啶-1-基-乙酮
  参考文献：
  名称：

  (E)-3-(Aryl(arylamino)methylene)indolin-2-one 衍生物：一种有效的合成方法及其抗癌活性评估

  摘要：

  使用有效的合成方法合成了一系列 (E)-3-(芳基(芳基氨基)亚甲基)indolin-2-one 衍生物。该方法涉及 3-bromo-3-(bromo(aryl)methyl)indolin-2-one 与取代苯胺的反应，通过亲核取代和在 DMF 中使用 NaHCO3 同时消除。还评估了产品对四种细胞系 HCT-116、A549、SKOV3 和 MDA-MB-231 的抗癌活性，几种化合物显示出中等抑制活性。

  DOI：

  10.3184/174751918x15166485941737

文献信息

• Shridhar, D. R.; Rao, K. Srinivasa; Singh, A. N., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1986, vol. 25, p. 1277 - 1280
  作者：Shridhar, D. R.、Rao, K. Srinivasa、Singh, A. N.、Rastogi, K.、Jain, M. L.

  DOI：——

  日期：——
• Shukla; Ahmad, Journal of the Indian Chemical Society, 1980, vol. 57, # 9, p. 950 - 953
  作者：Shukla、Ahmad

  DOI：——

  日期：——
• SHRIDHAR, D. R.;RAO, K. SRINIVASA;SINGH, A. N.;RASTOGI, K.;JAIN, M. L., INDIAN J. CHEM., 25,(1986) N 12, 1277-1280
  作者：SHRIDHAR, D. R.、RAO, K. SRINIVASA、SINGH, A. N.、RASTOGI, K.、JAIN, M. L.

  DOI：——

  日期：——
• Fenretinide Derivatives Act as Disrupters of Interactions of Serum Retinol Binding Protein (sRBP) with Transthyretin and the sRBP Receptor
  作者：José Angel Campos-Sandoval、Clara Redondo、Gemma K. Kinsella、Akos Pal、Geraint Jones、Gwen S. Eyre、Simon C. Hirst、John B. C. Findlay

  DOI：10.1021/jm200256g

  日期：2011.7.14

  Serum retinol binding protein (sRBP) is released from the liver as a complex with transthyretin (TTR), a process under the control of dietary retinol. Elevated levels of sRBP may be involved in inhibiting cellular responses to insulin and in generating first insulin resistance and then type 2 diabetes, offering a new target for therapeutic attack for these conditions. A series of retinoid analogues were synthesized and examined for their binding to sRBP and their ability to disrupt the sRBP-TTR and sRBP-sRBP receptor interactions. A number inhibit the sRBP-TTR and sRBP-sRBP receptor interactions as well as or better than Fenretinide (FEN), presenting a potential novel dual mechanism of action and perhaps offering a new therapeutic intervention against type 2 diabetes and its development. Shortening the chain length of the FEN derivative substantially abolished binding to sRBP, indicating that the strength of the interaction the polyene chain region. Differences in potency against the sRBP-TTR and sRBP-sRBP receptor interactions suggest variant effects of the compounds on the two loops of sRBP guarding the entrance of the binding pocket that are responsible for these two protein-protein interactions.
• (E)-3-(Aryl(arylamino)Methylene)Indolin-2-One Derivatives: An Efficient Synthetic Approach and Evaluation of their Cancer Inhibitory Activity
  作者：Hongwu Jiang、Zhiyuan Feng、Taiping Chen、Zicheng Li、Wencai Huang、Youfu Luo、Yinglan Zhao

  DOI：10.3184/174751918x15166485941737

  日期：2018.1

  A series of (E)-3-(aryl(arylamino)methylene)indolin-2-one derivatives were synthesised using an efficient synthetic approach. The method involved reaction of 3-bromo-3-(bromo(aryl)methyl)indolin-2-one with substituted anilines through nucleophilic substitution and a simultaneous elimination using NaHCO3 in DMF. The anticancer activity of the products against four cell lines, HCT-116, A549, SKOV3 and

  使用有效的合成方法合成了一系列 (E)-3-(芳基(芳基氨基)亚甲基)indolin-2-one 衍生物。该方法涉及 3-bromo-3-(bromo(aryl)methyl)indolin-2-one 与取代苯胺的反应，通过亲核取代和在 DMF 中使用 NaHCO3 同时消除。还评估了产品对四种细胞系 HCT-116、A549、SKOV3 和 MDA-MB-231 的抗癌活性，几种化合物显示出中等抑制活性。